SVRA才说没效果，又变成BREAKTHROUGH？

Phase 3 data June 12, 2019 did not meet primary endpoint. Noted October 2,
2019 that the FDA has recommended that a BLA not be filed. Open label data
due 1Q 2020.https://www.biopharmcatalyst.com/company/SVRA

Savara Granted Breakthrough Therapy Designation for Molgradex for the
Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
https://savara.gcs-web.com/news-releases/news-release-details/savara-granted-breakthrough-therapy-designation-molgradex

你们有谁看明白了？FDA一会儿说这药没效果，不能被递交申请。然后又来个
BREAKTHROUGH DESIGNATION，说明这药很有效果？这不是自己打自己的耳光？

有谁看明白了，给讲讲？

SVRA今天又涨了，创新高！

又变红了，一天的波动真大，有水平的可以做DT